R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

NCT00004009 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: tipifarnib

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]